Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Squamous Cell Carcinoma Invading a Transplanted Cornea

Eye- and Vision-Sparing Palladium-103 Plaque Radiation Therapy for a Functionally Monocular Patient

Semenova, Ekaterina, MD*; Finger, Paul T., MD*,†; Choi, Walter, MD*

doi: 10.1097/ICO.0000000000001730
Case Report

Purpose: To present a unique approach to eye and vision sparing for a patient with squamous cell carcinoma invading through a penetrating keratoplasty (PK) wound.

Methods: A 56-year-old functionally monocular man was found to have squamous cell carcinoma with intraocular invasion through a PK wound. Eye- and vision-salvaging palladium-103 plaque radiation was performed. An amniotic membrane graft was used to buffer and thus protect the cornea during the 7-day treatment. Leaded eye glasses were worn during the day to block emitted radiation and allow functional vision during irradiation.

Results: At 3.5 years status posttreatment, the tumor has regressed, PK has become progressively hazy (within the irradiated zone), and his vision is stable at 20/320. The epicorneal tumor has disappeared, and the intraocular tumor nodules are more highly reflective, but persistent. There has been no intraocular tumor progression, worsening of his glaucoma, or evidence of intraocular radiation vasculopathy.

Conclusions: Transcorneal intraocular tumor invasion was controlled using palladium-103 ophthalmic plaque radiation therapy applied through the natural and donor cornea. Definitive treatment resulted in local tumor control and preservation of vision.

*Department of Ophthalmology, Ocular Tumor Service, New York Eye and Ear Infirmary of Mount Sinai, New York, NY; and

The New York Eye Cancer Center, New York, NY.

Correspondence: Paul T. Finger, MD, The New York Eye Cancer Center, Fifth Floor, 115 East 61st St, New York City, NY 10065 (e-mail: pfinger@eyecancer.com).

The Eye Cancer Foundation supported this case report (http://www.eyecancercure.com).

The authors have no funding or conflicts of interest to disclose.

Received May 02, 2018

Received in revised form July 09, 2018

Accepted July 12, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.